How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (

    Website using assistance : Leihong Wu (

    Basic Information

    Gene Name: PPARA

    Description: peroxisome proliferator-activated receptor alpha

    Entrez Gene ID: 5465

    SwissProt Acc Number: Q07869

    RefSeq: NM_001001928

    It was suspected to be CHD related:

    ..The present study shows that R219K polymorphism of ABCA1 gene and G>C polymorphism in intron 7 of PPARA gene act cumulatively and synergistically in determining the risk of premature CAD...

    From PMID: 17608096, in Journal Acta Cardiol.? , 2007


    There were 7 potential papers with PPARA and CHD.

    23583468 "Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes."GeneMore Details
    20838448 A PPARalpha promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes.PloS oneMore Details
    19948975 Integrative predictive model of coronary artery calcification in atherosclerosis.CirculationMore Details
    18787507 Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes.Pharmacogenetics and genomicsMore Details
    16221474 The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).AtherosclerosisMore Details
    16763159 Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participants."Arteriosclerosis, thrombosis, and vascular biology"More Details
    16043164 "Contemporaneous carrier-state of two or three ""proatherosclerotic"" variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals."Clinica chimica acta; international journal of clinical chemistryMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.

    PPI interactions

    There were totally 38 unique genes interacted with PPARA. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    STAC3 Two-hybrid16189514|16189514 No
    NCOA1 Two-hybrid9407140|9626662 No
    EP300 Two-hybrid9407140|10336495|10336495 CHD related
    FABP1 Two-hybrid11226238|11226238 No
    NCOR1 Two-hybrid10336495|10336495|19955185 No
    PRIC285 Reconstituted Complex12189208 No
    RXRA Reconstituted Complex10195690 CHD related
    NCOR2 Co-crystal Structure11845213|19955185 No
    HSP90AA1 Affinity Capture-Western12482853|12482853|12482853 CHD related
    AIP Affinity Capture-Western12482853|12482853 No
    TRA@ Co-localization19782026 No
    SRC FRET12163133 CHD related
    SUMO1 Reconstituted Complex19955185|19955185 No
    TNP1 Two-hybrid21967852 No
    PPARA in vitro11698662,11845213 CHD related
    PRKCA in vitro16042408 CHD related
    PRKCD in vitro16042408 CHD related
    GADD45A in vitro10872826 No
    NRBF2 Two-hybrid10786636|10786636 No
    GADD45G Reconstituted Complex10872826|10872826 No
    Gadd45b Reconstituted Complex10872826 No
    RXRG Two-hybrid16169070 No
    DAP3 Reconstituted Complex10903152|10903152 No
    RELA Reconstituted Complex10542237 CHD related
    PPARGC1B Reconstituted Complex11733490 No
    AKAP13 Reconstituted Complex9627117|9627117 No
    POU1F1 Reconstituted Complex11891224 No
    PPARGC1A Reconstituted Complex10669761|10669761 CHD related
    MED24 Reconstituted Complex9653119|9653119 No
    LPIN1 Affinity Capture-Western20385772 No
    UBE2I Reconstituted Complex19955185 No
    MAPK1 in vitro10187842 CHD related
    DUT in vitro;in vivo;yeast 2-hybrid8910358 No
    MAPK3 in vitro10187842 CHD related
    NRIP1 in vitro;yeast 2-hybrid10022764,9626662 No
    MED1 in vitro;in vivo9653119 No
    NR1H3 in vitro;yeast 2-hybrid8621574 CHD related
    CHD9 in vitro;in vivo16554032 No

    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00636ClofibrateFor Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels. C10AB01;C10AB03
    approvedDB01039Fenofibrate"For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)"C10AB05
    approvedDB01241GemfibrozilFor treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.C10AB04
    approvedDB01393Bezafibrate"For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus)."C10AB02
    experimentalDB077243-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
    experimentalDB08483"(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid"